EUVIMEDEUVIMED entdecken
Crossref

Serum PCSK9 level as a potential biomarker relating to age, cholesterol and predicting major adverse cardiovascular event risk in hemodialysis patients

Yunxia Li, Wenxiu Chai, Panpan Cai, Ye Xin, Jianbo Shao

International Urology and Nephrology · 20.10.2025 · 58 (5) · 1775-1782

DOI: 10.1007/s11255-025-04776-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Urology and Nephrology, online erschienen am 20.10.2025. Verfasst von Yunxia Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Handan Central Hospital, Handan, 056000, Hebei, China. Hauptthemen laut MEDLINE: Renal Dialysis, Proprotein Convertase 9, Cardiovascular Diseases, Cholesterol. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates cholesterol metabolism, vascular inflammation, plaque formation, atherosclerosis, and renal injury. This study aimed to investigate the level of serum PCSK9 and its association with clinical characteristics and particularly major adverse cardiovascular event (MACE) risk in hemodialysis patients. METHODS: A Sum of 177 hemodialysis patients and 50 healthy subjects was included in this study. Serum PCSK9 level was determined by enzyme-linked immunosorbent assay. MaCE information is collected in hemodialysis patients with a median follow-up period of 15.8 months. RESULTS: PCSK9 level was 179.0 [interquartile range (IQR): 106.9-297.7] ng/mL in hemodialysis patients, which was higher than that of 121.0 (IQR: 76.1-185.1) ng/mL in healthy subjects (P 163.5 ng/mL independently predicted a higher MACE risk. CONCLUSION: Serum PCSK9 level correlates with age, TC, and LDL-C, and predicts a higher MACE risk in hemodialysis patients, indicating its potency as a prognostic biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal DialysisProprotein Convertase 9Cardiovascular DiseasesCholesterolKidney Failure, ChronicHumansMaleFemaleMiddle AgedBiomarkersAge FactorsAgedPredictive Value of TestsRisk AssessmentCase-Control StudiesAdult

Stichwörter der Autor:innen

Clinical characteristicsHemodialysisMACE riskPCSK9Serum level

Substanzen

Proprotein Convertase 9PCSK9 protein, humanBiomarkersCholesterol

Autor:innen und Institutionen

  • Department of Nephrology, Handan Central Hospital, Handan, 056000, Hebei, China.
  • Department of Ultrasound, Handan Central Hospital, No.15 Zhonghua Street, Hanshan District, Handan, 056000, Hebei, China. shaojianbokeyan@163.com.

Zitieren

APA

Li, Y., Chai, W., Cai, P., Xin, Y., & Shao, J. (2025). Serum PCSK9 level as a potential biomarker relating to age, cholesterol and predicting major adverse cardiovascular event risk in hemodialysis patients. International Urology and Nephrology, 58(5), 1775-1782. https://doi.org/10.1007/s11255-025-04776-9

Vancouver

Li Y, Chai W, Cai P, Xin Y, Shao J. Serum PCSK9 level as a potential biomarker relating to age, cholesterol and predicting major adverse cardiovascular event risk in hemodialysis patients. International Urology and Nephrology. 2025;58(5):1775-1782. doi:10.1007/s11255-025-04776-9

BibTeX
@article{Li2025,
  author = {Li, Yunxia and Chai, Wenxiu and Cai, Panpan and Xin, Ye and Shao, Jianbo},
  title = {Serum PCSK9 level as a potential biomarker relating to age, cholesterol and predicting major adverse cardiovascular event risk in hemodialysis patients},
  journal = {International Urology and Nephrology},
  year = {2025},
  volume = {58},
  number = {5},
  pages = {1775--1782},
  doi = {10.1007/s11255-025-04776-9}
}
Kostenlos starten →